Amsterdam UMC’s newest medical devices startup, HaemoPulse
April 23, 2019A new spin-off of Amsterdam UMC, location AMC, HaemoPulse, started in the first months of 2019. HaemoPulse will develop non-invasive optical technology for continuous real-time monitoring of blood hematocrit.
Being able to measure hematocrit in such a manner opens a wide range of clinical applications, such as tracking of fluid balance in critically ill patients in the ICU, or monitoring of fluid retention of dialysis patients between dialysis treatments. Current clinical techniques for such measurements are insufficiently accurate or require expensive, time-consuming, lab testing of invasively acquired blood samples.
HaemoPulse intends to provide the technology that provides doctors with critical information on fluid balance and blood hematocrit that they currently lack. The scientific founder, Dr. Alan Riordan, is an AMC researcher and the company is developing the technology with the biomedical optics research group of Prof. Ton van Leeuwen at AMC.
More news
Tackling learning difficulties in Academic Workplace
The Academic Workplace Rudolf Berlin Center (AW RBC) aims to make a meaningful contribution by supporting young people with learning disabilities through enhanced education and care.
News
Contribute to Amsterdam’s Future: test your innovation at SAIL and the Amsterdam Marathon
Are you looking for a testing ground for your innovation? SAIL and the Amsterdam Marathon present an excellent opportunity to test your ideas. These major events attract millions of visitors and come with sustainability, accessibility, and logistical challenges that need fresh solutions. The In Residence Events program allows you to test your innovation during these […]
News
VU researchers develop research equipment to identify contaminants in water
Water, comprising over 70% of our planet, is the source of all life. The presence of emerging contaminants in our water, including pharmaceuticals, pose serious health and environmental risks, such as DNA damage, reproductive issues, and cancer. New equipment to detect these contaminants developed by VU researchers has been sold to other research groups all over the world. Now the researchers are taking the next step, together with IXA, to expand sales to water companies worldwide as well as other applications such as food and drug discovery research.
News